Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Esperion Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Esperion Therapeutics, Inc.’s stock price such as:

• Esperion Therapeutics, Inc.’s current stock price and volume
• Why Esperion Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ESPR from analysts
• ESPR’s stock price momentum as measured by its relative strength

About Esperion Therapeutics, Inc. (ESPR)

Before we jump into Esperion Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Want to learn more about Esperion Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Esperion Therapeutics, Inc..

Esperion Therapeutics, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:47 PM, CST, Esperion Therapeutics, Inc.’s stock price was $2.040.

Esperion Therapeutics, Inc. is down 5.99% from its previous closing price of $2.170.

During the last market session, Esperion Therapeutics, Inc.’s stock traded between $2.030 and $2.210. Currently, there are approximately 236.68 million shares outstanding for Esperion Therapeutics, Inc..

Esperion Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Esperion Therapeutics, Inc. Stock Price History

Esperion Therapeutics, Inc.’s (ESPR) price is currently down 25.55% so far this month.

During the month of April, Esperion Therapeutics, Inc.’s stock price has reached a high of $2.780 and a low of $2.030.

Over the last year, Esperion Therapeutics, Inc. has hit prices as high as $4.175 and as low as $0.693. Year to date, Esperion Therapeutics, Inc.’s stock is down 44.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Esperion Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 15, 2026,, no analysts have changed their rating of Esperion Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Esperion Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Esperion Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Esperion Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Esperion Therapeutics, Inc. (ESPR) by visiting AAII Stock Evaluator.

Relative Price Strength of Esperion Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Esperion Therapeutics, Inc. has a weighted four-quarter relative price strength of 14.26%, which translates to a Momentum Score of 84 and is considered to be Very Strong.

Want to learn more about how Esperion Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Esperion Therapeutics, Inc. Stock Price: Bottom Line

As of April 16, 2026, Esperion Therapeutics, Inc.’s stock price is $2.040, which is down 5.99% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Esperion Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.